Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

by Kaze, A.D, Kim, S.C, Paik, J.M, Patorno, E., Zhuo, M.
Published 2022

Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study

by Desai, R.J, Khosrow-Khavar, F., Kim, S.C, Pawar, A., Weinblatt, M.E
Published 2022

Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study

by Jeong, T.-Y, Kim, S.C, Lee, J.-H, Lee, M.-K, Lee, S.Y, Sohn, S.-Y
Published 2022

Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries

by Hawley, C.E, Kim, S.C, Lauffenburger, J.C, Paik, J.M, Patorno, E., Wexler, D.J
Published 2022

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents

by Chin, K., Desai, R.J, Gerhard, T., Horton, D.B, Kim, S.C, Mahesri, M., Schneeweiss, S., Segal, J., Thambisetty, M., Varma, V.R
Published 2022

Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma

by Ahn, J.-Y, Cho, B.-K, Choi, W., Kim, J.H, Kim, S.C, Kim, S.Y, Kim, Y.-H, Lee, J.-P, Min, J., Oh, I.-H, Park, D.-Y, Sekhon, S.S, Shin, W.-R, Thai, N.Q
Published 2022